Antineutrophil antibodies in familial inflammatory bowel disease☆
References (24)
- et al.
A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
J Allergy Clin Immunol
(1990) - et al.
Antineutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal diseases
Gastroenterology
(1991) - et al.
A new type of perinuclear antineutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease
Immunobiology
(1990) - et al.
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity
Gastroenterology
(1992) - et al.
Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis
Gastroenterology
(1994) - et al.
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
Gastroenterology
(1987) - et al.
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
Lancet
(1990) - et al.
Autoantibodies to colonic cells and subcellular fractions in inflammatory bowel disease: do they exist?
J Autoimmun
(1990) - et al.
Familial occurrence of inflammatory bowel disease
N Engl J Med
(1991) - et al.
Antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
Gastroenterol Clin Biol
(1992)
Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role
Gut
Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease
Aust NZ J Med
Cited by (70)
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
2017, GastroenterologyIncreased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives
2013, Digestive and Liver DiseaseCitation Excerpt :Abnormal intestinal permeability has been found in unaffected relatives of patients with Crohn's disease [9–13] and increased levels of faecal calprotectin, a marker of subclinical inflammation, has also been reported in relatives of patients with either Crohn's disease or ulcerative colitis [14,15]. p-ANCA prevalence in unaffected first-degree relatives of ulcerative colitis patients is not uniform among studies, but it is almost similar to the general population [16–19], whereas ASCA are more expressed in unaffected first-degree relatives of Crohn's disease patients than in the general population, with a prevalence of 20–25% [20,21]. Mei et al. [22] also reported an increased prevalence of anti-OmpC in unaffected family members compared to healthy controls (15.5–18.7% vs 6%).
Inflammatory Bowel Disease
2013, Emery and Rimoin's Principles and Practice of Medical GeneticsNovel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
2010, Medical Clinics of North AmericaNovel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
2009, Gastroenterology Clinics of North AmericaCitation Excerpt :Some authors have reported that 16% to 30% of healthy first-degree relatives of patients with UC are positive for atypical p-ANCA.45,46 However, other authors were not able to confirm this finding.47,48 Among patients with Crohn disease, it has been consistently shown that 20% to 25% of healthy first-degree family members are ASCA positive.14–16
(Auto)Antibodies in Inflammatory Bowel Diseases
2008, Gastroenterology Clinics of North America
- ☆
Supported by the Crohn's in Childhood Research Association and the Middlesex Hospital Research and Development Fund.